top of page
Clinical Pipeline
Clinical Development Status
Allyx Therapeutics is advancing ALX-001, a first-in-class synapse-targeting therapy, through rigorous clinical investigations to address the core pathology of neurodegeneration.
Alzheimer's Disease
Status: Phase 2 Ready
Following successful Phase 1b results, ALX-001 is advancing into Phase 2 studies to evaluate impact on synaptic health.
Parkinson's Disease
Status: Phase 1b Completed
Clinical expansion into Parkinson's is underway, with the first patient recently treated under our IND application.
Our Studies
Extensive Phase 1 safety, tolerability, pharmacokinetics, and target engagement package to support Phase 2 studies.
bottom of page